| abstract |
Use of (a) an agent that decreases the expression, activity or level of VEGF-A, the agent selected from (i) an antibody that binds to VEGF-A or VEGFR-2 and decreases VEGF-A signaling, ( ii) inactive, mutated VEGF-A that binds VEGFR-2 and disrupts VEGF-A signaling, (iii) VEGFR-2 or a fragment thereof that binds VEGF-A and disrupts VEGF-A signaling , (iv) a VEGF-A or VEGFR-2 nucleic acid that can bind to a cellular VEGF-A or VEGFR-2 nucleic acid sequence and can inhibit the expression of VEGF-A or VEGFR-2, for example , an antisense, siRNA or ribozymes, (v) VEGF receptor tyrosine kinase inhibitors, for the preparation of a medicament for reducing chronic or acute UVB-induced skin damage, wherein the medicament further comprises (b) an agent that increases the expression, activity or level of a lymphangiogenic factor, where the lymphangiogenic factor is VEGF-C, VEGF-D or VEGFR-3, the agent selected from: (i) VEGF-C or -D polypeptide, or a biologically active fragment thereof, (ii) a nucleic acid encoding a VEGFC or -D polypeptide, or a biologically active fragment thereof, or (iii) a nucleic acid by VEGFR-3. |